Alberto Serrano-Pozo

List of Publications by Year
in descending order

58	10,233	117625	144013
papers	citations	34 h-index	57 g-index

66	66	66	13721
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Systematic review of human postâ€mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	40
2	Cyclic multiplex fluorescent immunohistochemistry and machine learning reveal distinct states of astrocytes and microglia in normal aging and Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, 30.	7.2	15
3	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain Communications, 2022, 4, .	3.3	11
4	APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurology, The, 2021, 20, 68-80.	10.2	399
5	Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration. Neurobiology of Disease, 2021, 149, 105225.	4.4	54
6	Reactive astrocyte nomenclature, definitions, and future directions. Nature Neuroscience, 2021, 24, 312-325.	14.8	1,098
7	Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease. Neurology, 2021, 96, e2414-e2428.	1.1	34
8	Differential gene expression data from the human central nervous system across Alzheimer's disease, Lewy body diseases, and the amyotrophic lateral sclerosis and frontotemporal dementia spectrum. Data in Brief, 2021, 35, 106863.	1.0	6
9	Hypoxia compromises the mitochondrial metabolism of Alzheimerâ€™s disease microglia via HIF1. Nature Aging, 2021, 1, 385-399.	11.6	43
10	Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimerâ€™s disease. Nature Aging, 2021, 1, 919-931.	11.6	13
11	Characterization of glial responses in Alzheimerâ€™s disease with cyclic multiplex fluorescent immunohistochemistry and machine learning. Alzheimer's and Dementia, 2021, 17, e050902.	0.8	0
12	Active deep learning to detect cognitive concerns in electronic health records. Alzheimer's and Dementia, 2021, 17, e055362.	0.8	1
13	Characterization of the 18 kDa translocator protein (TSPO) expression in postâ€mortem normal and Alzheimer's disease brains. Brain Pathology, 2020, 30, 151-164.	4.1	81
14	Meta-analysis of mouse transcriptomic studies supports a context-dependent astrocyte reaction in acute CNS injury versus neurodegeneration. Journal of Neuroinflammation, 2020, 17, 227.	7.2	56
15	Metaâ€analysis of mouse transcriptomic studies supports a contextâ€dependent astrocyte reaction in acute CNS injury versus neurodegeneration. Alzheimer's and Dementia, 2020, 16, e040699.	0.8	0
16	Brain transcriptomes and plasma proteins reveal upregulation of a proinflammatory signature in APOE e4 carriers. Alzheimer's and Dementia, 2020, 16, e041316.	0.8	0
17	Plasma biomarkers of neuroinflammation and vascular injury predict cognitive decline in patients with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e046134.	0.8	2
18	Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2146.	12.8	219

#	Article	IF	Citations
19	Tau molecular diversity contributes to clinical heterogeneity in Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 1256-1263.	30.7	262
20	Is Alzheimerâ€™s Disease Risk Modifiable?. Journal of Alzheimer's Disease, 2019, 67, 795-819.	2.6	73
21	Deciphering the Astrocyte Reaction in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 114.	3.4	202
22	Editorial: The Role of Glia in Alzheimer's Disease. Frontiers in Neurology, 2018, 9, 1161.	2.4	6
23	Four Decades of Research in Alzheimerâ€™s Disease (1975â€“2014): A Bibliometric and Scientometric Analysis. Journal of Alzheimer's Disease, 2017, 59, 763-783.	2.6	33
24	Acute and Chronic Sustained Hypoxia Do Not Substantially Regulate Amyloid-Î² Peptide Generation In Vivo. PLoS ONE, 2017, 12, e0170345.	2.5	8
25	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. Journal of Neuropathology and Experimental Neurology, 2016, 75, 516-526.	1.7	67
26	Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. American Journal of Pathology, 2016, 186, 375-384.	3.8	73
27	The Golgi-Localized Î³-Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid-Î² Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1). PLoS ONE, 2015, 10, e0129047.	2.5	17
28	<scp>APOE</scp>Îµ2 is associated with milder clinical and pathological <scp>A</scp>lzheimer disease. Annals of Neurology, 2015, 77, 917-929.	5.3	132
29	Inhibition of amyloid-Î² plaque formation by Î±-synuclein. Nature Medicine, 2015, 21, 802-807.	30.7	97
30	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathologica, 2015, 129, 757-762.	7.7	139
31	Alzheimer dementia with sparse amyloidâ€”AD mimic or variant?. Nature Reviews Neurology, 2015, 11, 674-675.	10.1	2
32	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 146.	5.2	79
33	Utility of neuropsychiatric tools in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease: quantitative and qualitative findings. International Psychogeriatrics, 2014, 26, 453-461.	1.0	15
34	Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Annals of Neurology, 2014, 75, 597-601.	5.3	90
35	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	7.7	1,060
36	A Phenotypic Change But Not Proliferation Underlies Glial Responses in Alzheimer Disease. American Journal of Pathology, 2013, 182, 2332-2344.	3.8	131

#	Article	IF	Citations
37	Studying synapses in human brain with array tomography and electron microscopy. Nature Protocols, 2013, 8, 1366-1380.	12.0	95
38	Dissecting phenotypic traits linked to human resilience to Alzheimerâ€™s pathology. Brain, 2013, 136, 2510-2526.	7.6	294
39	Mouse Gender Influences Brain Transduction by Intravascularly Administered AAV9. Molecular Therapy, 2013, 21, 1470-1471.	8.2	33
40	Mitochondrial Alterations near Amyloid Plaques in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2013, 33, 17042-17051.	3.6	156
41	Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2013, 125, 187-199.	7.7	67
42	Alzheimerâ€™s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron, 2013, 78, 631-643.	8.1	776
43	Examination of the Clinicopathologic Continuum of Alzheimer Disease in the Autopsy Cohort of the National Alzheimer Coordinating Center. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1182-1192.	1.7	89
44	Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 462-471.	1.7	163
45	Apolipoprotein E4 effects in Alzheimerâ€™s disease are mediated by synaptotoxic oligomeric amyloid-Î². Brain, 2012, 135, 2155-2168.	7.6	268
46	Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 694-701.	1.7	41
47	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid Î² Peptide. Journal of Neuroscience, 2012, 32, 15181-15192.	3.6	219
48	The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System. American Journal of Pathology, 2012, 181, 1426-1435.	3.8	369
49	Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a006189-a006189.	6.2	2,365
50	Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer's Disease. American Journal of Pathology, 2011, 179, 1373-1384.	3.8	379
51	Brain Oligomeric Î²-Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2011, 70, 360-376.	1.7	111
52	Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. Alzheimer Disease and Associated Disorders, 2010, 24, 220-226.	1.3	57
53	Beneficial effect of human anti-amyloid-Î² active immunization on neurite morphology and tau pathology. Brain, 2010, 133, 1312-1327.	7.6	138
54	Cardiac embolism in a Claude's syndrome without involvement of the red nucleus. European Journal of Neurology, 2007, 14, e1-e2.	3.3	2

#	Article	IF	Citations
55	Vincristine-induced acute neurotoxicity versus Guillain?Barrï¿½ syndrome: a diagnostic dilemma. European Journal of Neurology, 2007, 14, 826-828.	3.3	27
56	Spinal anterior artery territory infarction simulating an acute myocardial infarction. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1584-1584.	1.9	2
57	Sensory Polyneuropathy as Initial Manifestation of Endemic Leprosy in Spain. European Neurology, 2004, 52, 256-258.	1.4	5
58	Systemic and Local Hypoxia Synergize Through HIF1 to Compromise the Mitochondrial Metabolism of Alzheimer's Disease Microglia. SSRN Electronic Journal, 0, , .	0.4	0